2022-07-05-世界卫生组织-Immunization_Switzerland_2022_country_profile_16页_351kb

WHO and UNICEF Immunization Coverage Estimates for Switzerland (2021 Revision)

Introduction

On July 8, 2022, WHO and UNICEF provided country-specific estimates of immunization coverage for Switzerland based on data from 2010 to 2021. These estimates, with the next revision due July 15, 2023, are derived from national reports, surveys, administrative records, and empirical data sources. However, data quality varies, and estimates should always be interpreted with caution due to potential biases and lack of underlying probability models.

Methodology

• Data Sources: Estimates are based on national immunization reports, survey-based data (e.g., household surveys among children aged 12-23 or 24-35 months), administrative statistics, and population-based information.
• Graded Confidence (GoC): Confidence levels are assigned based on data support:
  • •••: Well-supported by reported data, surveys, and recalculated denominators.
  • ••: Supported by at least one data source but not challenged.
  • •: No accepted empirical data.
• Interpretation: No uncertainty measures (e.g., confidence intervals) provided. Coverage values are weighted averages or interpolations. Official, administrative, and survey data may differ slightly across sources.

Key Immunization Coverage Checkpoints for Switzerland

Switzerland's coverage varies by vaccine and year, with data for most vaccines available from 2010 onwards. Below are highlights for major vaccines, focusing on consistency and trends.

• DTP1: Coverage for the first dose of diphtheria, tetanus, and pertussis-containing vaccine ranged from 92% to 98% (average mid-2010s). High coverage (97-98%) with Grade of Confidence •• in 2020-2021.
• DTP3: Coverage for the third dose was consistently high from 95% to 98% (e.g., 96% in 2021) with GoC ••, indicating reliable data.
• Pol3: Third dose of polio vaccine coverage was strong, averaging 96% in recent years (96% in 2021), with GoC ••.
• BCG: Birth dose coverage was high overall (95-98%) from 2010-2021, but no data/NA for some years with GoC NA or R+ challenges.
• MCV1/2: First and second doses of measles-containing vaccines had coverage of 92-98% (e.g., MCV1 at 92% in 2021), with good confidence. MCV1 depends on nationally recommended schedules.
• IPV1: First dose of inactivated polio vaccine coverage reached 97-98% in 2021 with GoC ••, but older estimates were interpolated.
• HepB1/B3: Birth and third doses of hepatitis B vaccine showed variability, with HepB3 coverage increasing in 2018. Examples: HepB1 at 30-57% (lower in some years), HepB3 at 69-75%.
• Hib3: Third dose for Haemophilus influenzae type b vaccine coverage was stable at 95-96%.
• RotaC and PcV3: RotaC had no data, but PcV3 coverage showed incremental increases (from 37% in 2010 to 86-88% in later years), often with interpolation issues in earlier periods.

Health Outcomes and Noteworthy Details

• Most vaccines exhibit high coverage (>90%) in recent years, indicating robust immunization systems, but data interpolation was used for missing years.
• Changes in vaccination strategies (e.g., HepB vaccine transitioned to infants in 2018) are reflected in coverage trends.
• Recommended ages for doses vary (e.g., DTP and other vaccines targeted by 25-35 months), confirmed through card-based surveys or official reports.

Caveats and Disclaimers

• Estimates may be subject to bias from inaccurate numerator/denominator data.
• Always assess usage based on context; data should not be solely relied upon without professional judgment.
• Full details and earlier years are available via linked resources.